Partner Courtenay Brinckerhoff was quoted in a BioWorld article, “With BPCIA Dance Optional, Next Moves Up to Biosimilar Sponsors,” on July 24, 2015. The article discussed next steps for biosimilar sponsors after the Federal Circuit confirmed that the Biologic Price Competition and Innovation Act’s intricate patent information exchange is optional. Brinckerhoff said it’s likely that many biosimilar developers will choose not to follow the steps in place by BPCIA since it requires the biosimilar sponsor to give a copy of its application and other confidential manufacturing-related information to the reigning market champion.
